To investigate the molecular mechanisms leading to CD73 up‐ or downregulation following MAPKi treatment, we initially investigated alterations in CD73 expression in a panel of human and mouse cancer cell lines following relevant RAS‐MAPK‐targeted treatment, including MEK inhibitor (MEKi, trametinib) and EGFR‐TKI (gefitinib). The gene discussed is MAP2K7; the disease is cancer.